動物用医薬品市場は、予測期間中に8.5％の大幅な市場CAGRを示し、2028年末までに990億ドルを超える見込みです。人間の病気と同様に、動物も診断、治癒、予防接種を必要とする感染症にかかる可能性があります。飼いならされた動物や家禽における感染症の蔓延は、新しい方法や薬剤を削ぎ落とすために、製薬企業にやりがいのある学習経験を与えました。しかし、菜食主義の上昇パターンと菜食主義への動きが動物用医薬品市場の発展を妨げる主な要因と考えらます。
人獣共通感染症の発生の拡大とオンラインビジネスステージの進歩によって、動物用の仮想ショップや健康管理が進化しています。最近、いくつかの非営利団体が、動物に与えられるべきケアについて一般市民への指導を行っています。この動きが最近、動物用医薬品市場全体の発展を促しています。オンラインストアの普及、簡単なアクセシビリティ、限定的なアイテムなどが、ペット関連のものへの関心の高まりの背後にある重要な目的です。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING RATES OF PET OWNERSHIP
4.2.2 RISING ZOONOTIC & CHRONIC DISEASES ANIMALS
4.2.3 INCREASING MEAT CONSUMPTION
4.3 RESTRAINT
4.3.1 STRINGENT REGULATORY GUIDELINES PERTAINING TO VACCINES APPROVAL FOR ANIMALS
4.3.2 SHORTAGE OF VETERINARIANS
4.4 OPPORTUNITY
4.4.1 INCREASING INVESTMENTS IN VETERINARY HOSPITALS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES REVIEW/MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF BUYERS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19
5.3.1 IMPACT OF COVID-19 ON LIVESTOCK SUPPLY CHAIN & ANIMAL HEALTH
5.3.2 IMPACT OF COVID-19 ON ANIMAL DISEASE PREVENTION & CONTROL
5.3.3 IMPACT ON MEAT CONSUMPTION
5.3.4 IMPACT ON ANIMAL HEALTH MARKET
6 GLOBAL ANIMAL HEALTH MARKET, BY ANIMAL TYPE
6.1 OVERVIEW
6.2 FARM ANIMAL
6.2.1 CATTLE
6.2.2 SWINE
6.2.3 POULTRY
6.2.4 SHEEP & GOATS
6.2.5 OTHERS
6.3 COMPANION ANIMAL
6.3.1 DOG
6.3.2 CAT
6.3.3 EQUINE
6.3.4 OTHERS
7 GLOBAL ANIMAL HEALTH MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 PHARMACEUTICALS
7.2.1 PARASITICIDES
7.2.2 ANTI-INFECTIVES
7.2.3 ANTI-INFLAMMATORY
7.2.4 ANALGESICS
7.2.5 OTHERS
7.3 VACCINES
7.3.1 LIVE ATTENUATED VACCINES
7.3.2 INACTIVATED VACCINES
7.3.3 RECOMBINANT VACCINES
7.3.4 DNA VACCINES
7.3.5 OTHERS
7.4 FEED ADDITIVES
8 GLOBAL ANIMAL HEALTH MARKET, BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 ORAL
8.3 PARENTERAL
8.4 TOPICAL
8.5 OTHERS
9 GLOBAL ANIMAL HEALTH MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 VETERINARY HOSPITALS & CLINICS
9.3 RETAIL
9.4 E-COMMERCE
9.5 OTHERS
10 GLOBAL ANIMAL HEALTH MARKET, BY REGION
10.1 INTRODUCTION
10.2 AMERICAS
10.2.1 NORTH AMERICA
10.2.1.1 US
10.2.1.2 CANADA
10.2.2 LATIN AMERICA
10.3 EUROPE
10.3.1 WESTERN EUROPE
10.3.1.1 GERMANY
10.3.1.2 FRANCE
10.3.1.3 UK
10.3.1.4 ITALY
10.3.1.5 SPAIN
10.3.1.6 REST OF WESTERN EUROPE
10.3.2 EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 CHINA
10.4.2 INDIA
10.4.3 JAPAN
10.4.4 AUSTRALIA
10.4.5 SOUTH KOREA
10.4.6 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST
10.5.2 AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE ANIMAL HEALTH MARKET
11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE ANIMAL HEALTH MARKET
11.5 KEY DEVELOPMENT ANALYSIS
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
11.6.2 PARTNERSHIP/ ACQUISITION
11.6.3 MARKET EXPANSION
11.6.4 INVESTMENTS
11.7 FINANCIAL MATRIX
11.7.1 SALES, 2020
12 COMPANY PROFILES
12.1 ELANCO
12.1.1 COMPANY OVERVIEWS
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 MERCK & CO., INC.
12.2.1 COMPANY OVERVIEW
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 SWOT ANALYSIS
12.3.6 KEY STRATEGIES
12.4 CHANELLE PHARMA
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 SWOT ANALYSIS
12.4.6 KEY STRATEGIES
12.5 CEVA
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 SWOT ANALYSIS
12.5.6 KEY STRATEGIES
12.6 NUTRECO N.V.
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS/SERVICES OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIES
12.7 VETOQUINOL SA
12.7.1 COMPANY OVERVIEWS
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS/SERVICES OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIES
12.8 VIRBAC GROUP
12.8.1 COMPANY OVERVIEWS
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS/SERVICES OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIES
12.9 ZOETIS INC.
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS/SERVICES OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIES
12.10 HESKA CORPORATION
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS/SERVICES OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
